Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients

Author:

Xie Cen1,Zhou Jialan1,Guo Zitao1,Diao Xingxing1,Gao Zhiwei1,Zhong Dafang1,Jiang Haoyuan2,Zhang Lijia2,Chen Xiaoyan1

Affiliation:

1. Centre for Drug Metabolism and Pharmacokinetics Research; Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai; China

2. Jiangsu Hengrui Medicine Co., Ltd.; Liangyungang; China

Publisher

Wiley

Subject

Pharmacology

Reference39 articles.

1. Imatinib (Gleevec)-induced hepatotoxicity;Ayoub;J Clin Gastroenterol,2005

2. Drug metabolites in safety testing;Baillie;Toxicol Appl Pharmacol,2002

3. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers [abstract];Bello;J Clin Oncol,2005

4. Dasatinib-induced acute hepatitis;Bonvin;Leuk Lymphoma,2008

5. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity;Bort;J Pharmacol Exp Ther,1999

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3